CD8A and neoplasm: In ESC and intratumoral models, PD‐L1 nb delivered and expressed in ESCs or immune/tumor cells effectively mitigated the exhaustion of CD8+ T cells and concurrently increased the proportion of active and effective CD8+ T cells, enabling them to effectively kill tumor cells.